Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

被引：4
|
作者：
Broeckelmann, Paul J. [1 ,2 ]
Pluetschow, Annette [1 ,2 ]
Greil, Richard [3 ,4 ,5 ]
Zijlstra, Josee M. [6 ]
Illidge, Timothy [7 ]
Fossa, Alexander [8 ,9 ]
Meissner, Julia [10 ,11 ]
Zimmermann, Andreas [12 ]
Mathas, Stephan [13 ]
Thol, Felicitas [14 ]
Fuchs, Michael [1 ,2 ]
Engert, Andreas [1 ,2 ]
Baues, Christian [15 ,16 ]
机构：
[1] Univ Cologne, German Hodgkin Study Grp, Cologne, Germany
[2] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, Cologne, Germany
[3] Paracelsus Med Univ, Med Dept Hematol 3, Med Oncol Rheumatol & Infectiol, Salzburg, Austria
[4] Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Salzburg, Austria
[5] Canc Cluster Salzburg, Salzburg, Austria
[6] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands
[7] Univ Manchester, Manchester Acad Hlth Sci, Natl Inst Hlth & Res,Biomed Res Ctr,Fac Biol Med, Christie Hosp Natl Hlth Serv Fdn Trust,Div Canc S, Manchester, Lancs, England
[8] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway
[9] Oslo Univ Hosp, Oslo, Norway
[10] Heidelberg Univ, Med 5, Heidelberg, Germany
[11] Univ Heidelberg Hosp, Dept Internal Med 5, Heidelberg, Germany
[12] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Dept Hematol Oncol, Munich, Germany
[13] Charite Univ Med Berlin, Hematol Oncol & Tumor Immunol, Berlin, Germany
[14] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, NH, Germany
[15] Univ Hosp Cologne, Fac Med, Dept Radiooncol & Cyberknife Ctr, Cologne, Germany
[16] Univ Hosp Cologne, Cologne, Germany
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124351
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1547
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
    Shi, Yuankai
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Zhang, Qingyuan
    Hu, Jianda
    Zhou, Hui
    Xiong, Yan
    Liu, Peng
    LANCET HAEMATOLOGY, 2019, 6 (01): : E12 - E19
  • [32] Reasonable two-stage adaptive designs for single-arm phase II clinical trials
    Kashiwabara, Kosuke
    Matsuyama, Yutaka
    PHARMACEUTICAL STATISTICS, 2018, 17 (06) : 770 - 780
  • [33] Phase II two-stage single-arm clinical trials for testing toxicity levels
    Kim, Seongho
    Wong, Weng Kee
    COMMUNICATIONS FOR STATISTICAL APPLICATIONS AND METHODS, 2019, 26 (02) : 163 - 173
  • [34] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [35] Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
    Martin-Broto, Javier
    Hindi, Nadia
    Grignani, Giovanni
    Martinez-Trufero, Javier
    Redondo, Andres
    Valverde, Claudia
    Stacchiotti, Silvia
    Lopez-Pousa, Antonio
    D'Ambrosio, Lorenzo
    Gutierrez, Antonio
    Perez-Vega, Herminia
    Encinas-Tobajas, Victor
    de Alava, Enrique
    Collini, Paola
    Pena-Chilet, Maria
    Dopazo, Joaquin
    Carrasco-Garcia, Irene
    Lopez-Alvarez, Maria
    Moura, David S.
    Lopez-Martin, Jose A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [36] Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma
    Venkatesh, H
    Di Bella, N
    Flynn, TP
    Vellek, MJ
    Boehm, KA
    Asmar, L
    CLINICAL LYMPHOMA, 2004, 5 (02): : 110 - 115
  • [37] PENPULIMAB FOR RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN'S LYMPHOMA (CHL): EXTENDED FOLLOW-UP OF THE MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
    Song, Yuqin
    Zhou, Keshu
    Jin, Chuan
    Qian, Zhengzi
    Hou, Ming
    Fan, Lei
    Li, Fei
    Ding, Kaiyang
    Zhou, Hui
    Li, Xiaoling
    Chen, Bing
    Sun, Xiuhua
    Song, Xianmin
    Jiang, Ming
    Zhang, Qingyuan
    Liu, Lihong
    Yu, Guohua
    Hu, Yu
    Zhao, Zheng
    Liu, Ligen
    Xue, Hongwei
    Luo, Jun
    He, Bai
    Yao, Zhifang
    Xu, Fenghua
    Zhao, Min
    Li, Baiyong
    Xia, Yu
    Zhu, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A598 - A598
  • [38] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Optimal Two-stage Designs for Single-arm Phase II Oncology Trials with Two Binary Endpoints
    Kunz, C. U.
    Kieser, M.
    METHODS OF INFORMATION IN MEDICINE, 2011, 50 (04) : 372 - 377
  • [40] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Johnston, P. B.
    Lewis, L. T.
    Rogerio, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345